Bristol Myers Squibb is set to launch three prescription medications on TrumpRx.gov starting Monday, offering substantial discounts ranging from 40% to 90% off retail prices [1]. The drugs include Sotyktu, which treats moderate-to-severe plaque psoriasis and will be available for $743, a 90% reduction from its retail price of $7,135.55 [1]. Zeposia, used for relapsing forms of multiple sclerosis, will be discounted by 88% to 90% [1]. Orencia SC, a weekly injection for moderate-to-severe rheumatoid arthritis, will see a 40% price reduction [1].
A White House official noted that Bristol Myers Squibb is the latest major pharmaceutical company to offer reduced prices following tariff pressure from President Donald Trump [1]. The ongoing negotiations with pharmaceutical companies have resulted in more medications being added to the government website, with Bristol Myers Squibb's additions following recent listings from Amgen and GSK [1]. Amgen's Amjevita, which treats rheumatoid arthritis, psoriasis, and ulcerative colitis, is available at an 80% discount, priced at $299 compared to its original $1,484 [1]. GSK is offering Incruse for COPD at a 55% discount ($159.20), and other drugs such as Arnuity, Relenza, and Anoro at discounts ranging from 10% to 51% [1].
Market reaction to these developments is reflected in modest gains for Amgen and GSK, with Amgen's stock up 0.07% to $349.00 and GSK rising 0.77% to $54.25 [1]. The White House continues to promote TrumpRx.gov as Americans seek ways to reduce medical expenses [1].
Prescription drug costs have shown contrasting trends under different administrations. According to Bureau of Labor Statistics data, prices increased by 10.4% from January 2021 to January 2025 under the Biden administration, while under the Trump administration, prices rose only 0.2% from January 2025 through February 2026 [1].
CONCLUSION
Bristol Myers Squibb's addition of three deeply discounted drugs to TrumpRx.gov marks a significant move in the ongoing effort to lower prescription costs for Americans. The initiative, supported by other pharmaceutical companies like Amgen and GSK, has led to modest positive market reactions. The White House's continued push for discounted medications is likely to further impact drug pricing trends and consumer access.